{
  "name" : "zero.sci-hub.se_5755_c8c5cd989e69fe0978f86d9e2da9e4fb_song2016.pdf",
  "metadata" : {
    "source" : "META",
    "title" : "CatalaseLoaded TaOx Nanoshells as BioNanoreactors Combining HighZ Element and Enzyme Delivery for Enhancing Radiotherapy",
    "authors" : [ "Guosheng Song", "Yuyan Chen", "Chao Liang", "Xuan Yi", "Jingjing Liu", "Xiaoqi Sun", "Sida Shen", "Kai Yang", "Zhuang Liu" ],
    "emails" : [ "zliu@suda.edu.cn", "TaOx@Cat", "TaOx@Cat-PEG" ],
    "sections" : [ {
      "heading" : null,
      "text" : "© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim 1wileyonlinelibrary.com\nC o m m u n iC a tio n"
    }, {
      "heading" : "Catalase-Loaded TaOx Nanoshells as Bio-Nanoreactors",
      "text" : ""
    }, {
      "heading" : "Combining High-Z Element and Enzyme Delivery for",
      "text" : ""
    }, {
      "heading" : "Enhancing Radiotherapy",
      "text" : ""
    }, {
      "heading" : "Guosheng Song, Yuyan Chen, Chao Liang, Xuan Yi, Jingjing Liu, Xiaoqi Sun, Sida Shen,",
      "text" : ""
    }, {
      "heading" : "Kai Yang, and Zhuang Liu*",
      "text" : "Dr. G. Song, Y. Chen, C. Liang, J. Liu, X. Sun, S. Shen, Prof. Z. Liu Institute of Functional Nano and Soft Materials (FUNSOM) Collaborative Innovation Center of Suzhou Nano Science and Technology Soochow University Suzhou, Jiangsu 215123, P. R. China E-mail: zliu@suda.edu.cn X. Yi, Prof. K. Yang School of Radiation Medicine and Protection and School for Radiological and Interdisciplinary Sciences (RAD-X) Medical College of Soochow University Suzhou, Jiangsu 215123, P. R. China\nDOI: 10.1002/adma.201602111\nproposed for improvement of tumor oxygenation, including the employment of the mild photothermal effect to increase intratumoral blood flow, and the use of near-infrared laser to trigger burst-release oxygen from perfluorocarbon loaded hollow Bi2Se3 nanoparticles saturated with oxygen, so as to enhance the therapeutic efficacy of RT.[6c,d] Moreover, since malignant cancerous cells would produce excessive amounts of H2O2 and cause significant increase of H2O2 level in the tumor microenvironment, MnO2 nanoparticles that are able to act as a catalyst to induce the decomposition of H2O2 and generation of O2 have been explored to overcome hypoxia-associated RT resistance by challenging the hypoxic tumor microenvironment.[6a,b,e]\nBeing nontoxic and bio-inert, tantalum which has been widely used in clinical implants, artificial joints, and stents, as a high-Z element, possesses a large X-ray attenuation coefficient comparable to gold, a commonly explored radio-sensitizing element (e.g., gold nanoparticles).[7] In this work, we thus design a novel type of bio-nanoreactors by encapsulating catalase (Cat), an enzyme that can rapidly decompose H2O2 into H2O and O2, within tantalum oxide (TaOx) nanoshells. After loading catalase into hollow TaOx cavity via a simple and mild one-step method, the obtained TaOx@Cat nanoparticles are then functionalized with polyethylene glycol (PEG). In this integrated bio-nanoreactor, the mesoporous TaOx shell is supposed to: (i) concentrate radiation energy within the tumor to enhance radiationinduced DNA damage; (ii) enable the free exchange of substrate H2O2 and product O2 and keep high catalytic activity/stability of catalase; (iii) effectively deliver catalase into the tumor by the enhanced permeability and retention (EPR) effect. With such TaOx@Cat-PEG as a radiosensitizer as well as a bio-nanoreactor to decompose tumor endogenic H2O2 and relieve tumor hypoxia, greatly enhanced cancer radiotherapy performance is realized with a mouse tumor model, without rendering appreciable toxic effect to the treated animals.\nA one-pot method has been developed to prepare TaOx hollow nanospheres, via simple addition of tantalum ethoxide into the mixture of water and ethanol (V:V = 10:1) at room temperature. The as-prepared product showed hollow structure with average diameter of 119 ± 34 nm, as revealed by transmission electron microscopy (TEM) imaging (Supporting Information, Figure S1a). Magnification of their shells exhibited porous structure (Supporting Information, Figure S1b). The hollow cavity of TaOx was probably built up from ultrasmall tantalum oxides species after ultrafast sol–gel reaction of tantalum ethoxide.[7a,b]\nThereby, enzyme-loaded nanoreactors were constructed on the basis of this mild preparation technology. As shown in\nRadiotherapy, also named radiation therapy (RT), is an extensively used cancer treatment strategy in the clinic together with surgery and chemotherapy.[1] During RT, ionizing radiation can directly cause DNA damages and produce oxygen radicals to kill cancer cells.[1a,d] The degree of cellular damages caused by ionizing radiation is highly dependent on the level of oxygen, which plays a critical role in the process of radiation-induced cell killing via a number of different mechanisms.[1c] For instance, oxygen molecules can stabilize DNA damages caused by ionizing radiation so as to prevent DNA self-repair by cells, enhancing cell killing during radiotherapy.[1d,2] However, the inadequate oxygen supply inside solid tumors makes the tumor microenvironment more hypoxic than normal tissues, resulting in hypoxia-associated radiotherapy resistance, a negative prognostic factor for radiotherapy.[3] On the other hand, when the radiation beam (e.g., X-ray) is applied on the tumor during radiotherapy, it could also cause significant damages to normal tissues that it passes by, while only a small portion of the incident radiation energy is absorbed by the tumor.[4] Therefore, developing effective methods to overcome tumor hypoxia and concentrate the radiation energy in the tumor would be helpful to enhance cancer radiotherapy.\nNanomedicine approaches recently have attracted much attention for the improvement of cancer therapy.[5] Many high-Z materials, such as noble metal and semiconducting nanoparticles that are able to absorb X-ray and emit photoelectrons or Auger electrons, have been used as radiosensitizers to sensitize RT by depositing irradiation energy inside the tumor.[5a,b,e] In the meanwhile, there have also been substantial efforts aiming at overcoming tumor hypoxia using nanomedicine strategies.[3c,6] In our recent studies, two strategies have been\nAdv. Mater. 2016, DOI: 10.1002/adma.201602111\n2 wileyonlinelibrary.com © 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nC o\nm m\nu n\niC a ti\no n\nFigure 1a, catalase was in situ encapsulated into hollow nanospheres of TaOx by adding tantalum precursor into catalasecontaining water/ethanol mixture solution at a controlled rate at room temperature. Due to the extremely fast reaction speed, catalase would be directly encapsulated in the cavity of the formed hollow TaOx nanostructure without any additional bioconjugation reaction. The yielded TaOx@Cat product showed a clear hollow nanostructure with more uniform size of 127 ± 16 nm (Figure 1b), and their shell also showed porous structure (Figure 1c). The hollow structure of TaOx@ Cat nanospheres was further confirmed by the high-angle annular dark-field scanning TEM (HAADF-STEM)-based elemental mapping (Figure 1d) and energy dispersive spectra (Supporting Information, Figure S2a). As revealed by X-ray photoelectron spectroscopy, such TaOx@Cat hollow nanospheres consisted of pentavalent tantalum (TaV) (Supporting Information, Figure S2b). X-ray diffraction pattern suggested the amorphous structure of TaOx (Supporting Information, Figure S2c). The N2 adsorption–desorption isotherm curves of TaOx@Cat showed a characteristic type IV isotherm (Supporting Information, Figure S3a), further demonstrating their mesoporous structure.[5f,8] The specific surface area of TaOx@Cat was measured to be 82.5 m2 g–1, while its average pore diameter was calculated to be 3.9 nm with a narrow size distribution (Supporting Information, Figure S3b). The mesoporous shell of TaOx is expected to not only allow H2O2 to diffuse into the cavity and get in touch with catalase, but also shield off catalase from outside proteases to improve its stability. A layer by layer (LBL) polymer coating method was then used to modify TaOx@Cat nanospheres.[6d] Harsh experiment steps were not allowed in the surface modification process due to enzyme existing within TaOx nanspheres. TaOx@Cat nanospheres were coated with cationic polyallylamine hydrochloride and anionic polyacrylic acid in sequence, and then conjugated with amine-terminated PEG (NH2-PEG, Mw = 5 K). The successful LBL coating was demonstrated by the alternative change of zeta potentials (Supporting Information,\nAdv. Mater. 2016, DOI: 10.1002/adma.201602111\nFigure 1. Synthesis and characterization of TaOx@catalase hollow nanospheres. a) A scheme showing the in situ encapsulation of catalase into hollow nanospheres of TaOx and the subsequent PEGylation. b) TEM image and (c) magnified TEM image of TaOx@Cat. d) HAADF-STEM image and elemental mapping. The element maps showed the uniform distribution of Ta (red) and O (green). e) The O2 concentration changes in H2O2 solutions after addition of TaOx@BSA and TaOx@Cat, as measured by a portable dissolved oxygen meter. Inset is the corresponding photograph of these three solutions. f) The O2 concentration changes in H2O2 solutions (750 µM) after incubation of various concentrations of TaOx@Cat-PEG (0–60 μg mL–1). g) The relative enzymatic activity changes of free catalase and TaOx@Cat-PEG after protease K digestion for different periods of time.\n3wileyonlinelibrary.com© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nC o m m u n iC a tio n Figure S4a) and stable hydrodynamic sizes (Supporting Information, Figure S4b) of those nanoparticles.\nTo figure out encapsulation efficiency and loading capability of catalase, the amount of encapsulated catalase was determined by bicinchoninic acid protein assay that is a detergentcompatible formulation for the colorimetric detection and quantitation of total protein.[9] The encapsulation efficiency of catalase in TaOx@Cat was measured to be 14%, while the loading capability of catalase in TaOx@Cat was 137 μg enzymes per milligram of Ta. After being encapsulated into polymer or inorganic matrices, enzymes may lose some of their activities.[10] The catalase activity was determined by the Góth method.[11] The TaOx@Cat maintained about 21% of enzymatic activity of equivalent free catalase molecules. When bovine serum albumin (BSA) was used to replace catalase, the obtained TaOx@BSA nanospheres (Supporting Information, Figure S1c,d), which showed similar sizes to TaOx@Cat, exhibited no catalytic activity to H2O2 (Figures 1e). Although the relative enzymatic activity of catalase loaded inside nanoshells was decreased, the encapsulated catalase still possessed high catalytic activity toward H2O2 (Figures 1e). As measured by a portable dissolved oxygen meter, a rapid rise of O2 concentration was observed after addition of TaOx@Cat-PEG into H2O2 aqueous solution (Figure 1f; Supporting Information, Figure S5a). We further evaluated the enzymatic stability of TaOx@Cat-PEG compared to free catalase against proteases, which is present in many physiological environments.[12] While free catalase was quickly digested and completely lost its activity after incubation with protease K for 3 h, catalase encapsulated in TaOx@Cat-PEG was well protected against protease\nK and kept ≈58% of its initial activity after the same treatment (Figure 1g). Moreover, TaOx@Cat-PEG only lost less than 5% of enzymatic activity, after ten circulations of 1 h incubation and centrifugation, demonstrating that catalase in TaOx@CatPEG was stably encapsulated inside nanoshells without significant leakage (Supporting Information, Figure S5b). Therefore, although the relative activity of catalase decreased after being encapsulated in TaOx@Cat-PEG, its enzymatic stability was greatly enhanced.\nNext, we evaluated the RT enhancement effect of TaOx@ Cat-PEG in vitro. Both TaOx@BSA-PEG and TaOx@Cat-PEG induced no obvious cytotoxic effect on 4T1 murine breast cancer cells (Supporting Information, Figure S6), despite the efficient cellular uptake of those nanoparticles (Supporting Information, Figure S7). For in vitro radiotherapy, 4T1 cancer cells were treated with X-ray with the photon energy at 140 keV at the radiation doses of 2, 4, and 6 Gy, in the presence of TaOx@Cat-PEG (50 μg mL–1) or TaOx@BSA-PEG (50 μg mL–1). Then the clonogenic survival assay was used to evaluate the efficacy of RT in vitro (Figure 2b). Compared to cells without nanoparticle treatment, cells treated with TaOx@BSA-PEG exhibited lower percentages of viable cell colonies after X-ray irradiation, indicating the efficient radio-sensitization effect of TaOx. More interestingly, cells treated with TaOx@Cat-PEG showed further enhanced inhibition of viable cell colonies post RT compared to the RT sensitization effect of TaOx@BSAPEG, demonstrating that catalase loaded inside nanoshells could further enhance radiotherapy, likely by an increase of the intracellular oxygen level via decomposing endogenic H2O2 secreted by tumor cells.[3c,13] Immunofluorescently labeling for\nAdv. Mater. 2016, DOI: 10.1002/adma.201602111\n4 wileyonlinelibrary.com © 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nC o\nm m\nu n\niC a ti\no n γ-H2AX, a marker of double-strand DNA breaks, was then con-\nducted to evaluate the DNA damage caused by X-ray post RT (Figure 2c,d). Consistent with the cell colony assay results, it was found that TaOx@Cat-PEG + X-ray produced the highest level of DNA damage compared to all other groups including that with TaOx@BSA-PEG + X-ray treatment, which although appeared to be more effective than RT alone in the absence of nanoparticles. Therefore, TaOx@Cat-PEG could greatly increase X-ray induced DNA damage and thus inhibit proliferation of cancer cells.\nNext, we wondered whether TaOx@Cat-PEG could target tumors via the EPR effect. The tumor uptake was determined to be 6.1% ID g–1 by the measurement of inductively-coupled plasma atomic-emission spectroscopy at 24 h post intravenous (i.v.) injection of TaOx@Cat-PEG into 4T1 tumor-bearing mice (Supporting Information, Figure S8). Since catalase could efficiently convert H2O2 into H2O and O2, we therefore exploited TaOx@Cat-PEG to overcome tumor hypoxia in vivo. Hypoxiainducible factor (HIF)-1α staining assay (Figure 3a) and hypoxiaprobe (pimonidazole) immunohistochemical assay (Supporting Information, Figure S9) were performed by staining hypoxia areas with anti-HIF-1α antibody (green) and anti-pimonidazole antibody (yellow), respectively, for tumors on mice either 6 h post intratumoral (i.t.) local injection of TaOx@Cat-PEG (TaOx dose = 15 mg kg–1, catalase dose = 1.05 mg kg–1), or 24 h post i.v. injection of TaOx@Cat-PEG (TaOx dose = 60 mg kg–1, catalase dose = 4.2 mg kg–1). Tumors from untreated mice, mice with i.t. injection of TaOx@BSA-PEG (TaOx dose = 15 mg kg–1), as well as mice with either i.t. or i.v. injection of free catalase (equivalent enzymatic activity with TaOx@Cat-PEG) were used as control. While TaOx@BSA-PEG (i.t.) treatment showed no appreciable effect on the tumor hypoxia, tumors treated with TaOx@Cat-PEG (either i.t. or i.v. injection) showed greatly weakened HIF-1α (green) and pimonidazole (yellow) stained hypoxic signals, indicating the significantly reduced hypoxia owing to the decomposition of endogenic H2O2 in the tumor microenvironment induced by catalase inside TaOx@Cat-PEG. On the other hand, while i.t. injection of free catalase was able to lower the hypoxia level in the tumor, i.v. injection of catalase appeared to be ineffective on the tumor hypoxia status, likely owing to the limited tumor retention of catalase as well as its enzymatic degradation during blood circulation after systemic administration. By contrast, TaOx@Cat-PEG is able to effectively deliver the loaded catalase into tumor after i.v. injection via the EPR effect while protecting it from degradation.\nNext, we ought to test the possibility of using TaOx@Cat-PEG to enhance in vivo radiotherapy. In our experiment, 4T1 tumorbearing mice were randomly divided into different groups (n = 5 per group) in two separated experiments, group 1: PBS; Group 2: TaOx@Cat-PEG; Group 3: X-ray irradiation without nanoparticle injection (RT alone); Group 4: TaOx@ BSA-PEG + RT; Group 5: TaOx@Cat-PEG + RT. For i.t. local treatment, the TaOx dose for TaOx@Cat-PEG and TaOx@ Cat-PEG was 15 mg kg–1, while the X-ray dose was 6 Gy (photon energy = 140 keV) (Figure 3d). Whereas for i.v. treatment, higher doses of TaOx@Cat-PEG and TaOx@CatPEG (60 mg kg–1 of TaOx) as well as X-ray (8 Gy) were used (Figure 3e). The photographs of representative mice in different groups were shown in the Supporting Information, Figure S10.\nFor both i.t. and i.v. treatment experiments, TaOx@BSA-PEG + RT (Group 4) offered more significant tumor growth inhibition effect compared to RT alone (Group 3), while TaOx@CatPEG + RT (Group 5) appeared to be the most effective in tumor growth inhibition among all groups (Figure 3d,e). Notably, i.t. injection of free catalase, although could also enhance the RT efficacy (Supporting Information, Figure S11), appeared to be less effective in RT sensitizing compared to TaOx@Cat-PEG (either i.t. or i.v.). Therefore, simply enhancing tumor oxygenation with free catalase may not be sufficient to render the most efficient RT sensitization.\nTo further evaluate RT sensitizing efficacy, two days after conducting various treatments, tumors from different groups (with i.v. treatment) were dissected for terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) staining and hematoxylin and eosin (H&E) staining. Micrographs of TUNEL and H&E (Figure 3f) stained tumor slices clearly illustrated that TaOx@Cat-PEG + RT (Group 5) produced more severe damages to tumor cells compared to the other groups. Such remarkable RT sensitizing effect of TaOx@ Cat-PEG could thus be attributed to the factors that: (i) Ta element is known to strongly absorb X-ray and thus could enable the deposition of radiation energy within the tumor to sensitize RT, (ii) catalase loaded inside TaOx nanospheres could effectively improve the tumor oxygenation by decomposing endogenic H2O2 in the tumor microenvironment.\nWe then evaluated the potential in vivo toxicity of TaOx@ Cat-PEG nanospheres by blood biochemistry and hematology analysis for mice i.v. injected with TaOx@Cat-PEG (60 mg kg–1) (Supporting Information, Figure S12). Most of the measured parameters for TaOx@Cat-PEG treated mice were found to be normal at different time points compared with those of untreated healthy mice. Furthermore, the histological examination of main organs in TaOx@Cat-PEG treated mice also exhibited no apparent histopathological abnormalities or lesions (Supporting Information, Figure S13). Therefore, from the blood biochemistry, hematological and histopathological results, no apparent toxicities induced by TaOx@Cat-PEG in vivo were observed at our tested dose within 30 d.\nIn this study, we have developed a simple and mild method to encapsulate catalase into hollow TaOx nanospheres as bionanoreactors. It should be noted that encapsulation of fragile biomolecules such as enzymes inside inorganic nanostructures is often difficult because many inorganic nanoparticles are synthesized under harsh experimental conditions involving strong acid/base, pure organic solvents, high temperatures, or tedious synthetic procedures, that are incompatible with biomacromolecules.[14] There is neither alkali/acidic catalysts nor high reaction temperature in our synthetic process, which is compatible with biomacromolecules such as enzymes. Moreover, the catalase was directly encapsulated in the cavity of hollow structure without any additional bioconjugations.[10] This fascinating strategy is featured with simple/mild preparation, efficient biomacromolecular encapsulation, and thus would be superior to conventional sequential growth method for nanoreactors.[15]\nIn such obtained TaOx@Cat-PEG system with highly integrated functionalities, the TaOx nanoshell is able to not only effectively deposit X-ray irradiation energy within tumor by itself and significantly increase radiation-induced DNA damage,\nAdv. Mater. 2016, DOI: 10.1002/adma.201602111\n5wileyonlinelibrary.com© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nC o m m u n iC a tio n\nAdv. Mater. 2016, DOI: 10.1002/adma.201602111\nFigure 3. In vivo overcoming tumor hypoxia and cancer treatment. a) Micrographs of tumor slices with cell nuclei, blood vessels, and hypoxia areas stained with DAPI (blue), anti-CD31 antibody (red), and HIF-1α antibody (green), respectively. b) Quantification of tumor hypoxia (positive in HIF1α) for different groups. c) Quantification of relative blood vessels area for different groups. The immunofluorescence images showed dramatically enhanced oxygenation level for tumors treated with TaOx@Cat-PEG after either i. t. or i. v. injection. Free catalase, by contrast, could relieve tumor hypoxia by only i.t. local injection but not by i.v. systemic injection. d,e) In vivo cancer treatment in a mouse tumor model. Five groups of mice were used: Group 1: PBS; Group 2: TaOx@Cat-PEG (i. t. 15 mg kg–1 or i. v. 60 mg kg–1); Group 3: X-ray irradiation without nanoparticle injection (RT alone); Group 4: TaOx@BSA-PEG (i. t. 15 mg kg–1 or i. v. 60 mg kg–1) + RT; Group 5: TaOx@Cat-PEG (i. t. 15 mg kg–1 or i. v. 60 mg kg–1) + RT. The X-ray radiation dose was 6 Gy for i. t. treatment and 8 Gy for i. v. treatment, respectively. d) Tumor growth curves of different groups of mice after i. t. treatment. e) Tumor growth curves of different groups of mice after i. v. treatment. f) Micrographs of TUNEL and H&E stained tumor slices collected from different groups of mice 2 d after treatments in the i.v. treatment experiment (e). P values: *P < 0.05, **P < 0.01.\n6 wileyonlinelibrary.com © 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nC o\nm m\nu n\niC a ti\no n\nAdv. Mater. 2016, DOI: 10.1002/adma.201602111\nbut also to deliver catalase into tumor via EPR effect and greatly improve catalytic stability of catalase. The bio-nanoreactor TaOx@Cat-PEG can efficiently decompose endogenic H2O2 inside the tumor microenvironment and thus improve tumor oxygenation, further overcoming the hypoxia-associated radioresistance of tumors. As a result, a remarkable synergistic RT sensitization effect is achieved by treatment with TaOx@CatPEG, which meanwhile shows no appreciable in vivo toxicity to animals at our tested dose. Therefore, this work presents an attractive nanotechnology approach for effective enhancement of radiation therapy, through integrating high-Z element for radio-sensitizing, as well as encapsulation/delivery of enzymes to challenge the tumor microenvironment unfavorable for RT (e.g., hypoxia). Moreover, this strategy may be extended to the design of other types of bio-nanoreactors with intriguing applications in biomedical therapy and imaging.\nSupporting Information Supporting Information is available from the Wiley Online Library or from the author."
    }, {
      "heading" : "Acknowledgements",
      "text" : "This work was partially supported by the National Natural Science Foundation of China (Grants Nos. 51525203 and 51302180), the National “973” Program of China (2012CB932601), a Project funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions, and Post-doctoral science foundation of China (Grant No. 2014M561706). All animal experiments were conducted under protocols approved by the Soochow University Laboratory Animal Center.\nReceived: April 21, 2016 Revised: May 13, 2016\nPublished online:\n[1] a) P. Wardman, Clin. Oncol. 2007, 19, 397; b) A. C. Begg, F. A. Stewart, C. Vens, Nat. Rev. Cancer 2011, 11, 239; c) E. E. Deschner, L. H. Gray, Radiat. Res. 1959, 11, 115; d) B. J. Moeller, R. A. Richardson, M. W. Dewhirst, Cancer Metastasis Rev. 2007, 26, 241. [2] M. Yu, M. Dai, Q. Liu, R. Xiu, Cancer Treat. Rev. 2007, 33, 757. [3] a) X. Sun, X.-F. Li, J. Russell, L. Xing, M. Urano, G. C. Li,\nJ. L. Humm, C. C. Ling, Radiother. Oncol. 2008, 88, 269; b) M. R. Horsman, J. Overgaard, Clin. Oncol. 2007, 19, 418; c) H. Chen, J. Tian, W. He, Z. Guo, J. Am. Chem. Soc. 2015, 137, 1539; d) J. M. Brown, W. R. Wilson, Nat. Rev. Cancer 2004, 4, 437; e) K. L. Bennewith, S. Dedhar, BMC Cancer 2011, 11, 504. [4] a) E. L. Jones, L. R. Prosnitz, M. W. Dewhirst, P. K. Marcom, P. H. Hardenbergh, L. B. Marks, D. M. Brizel, Z. Vujaskovic, Clin.\nCancer Res. 2004, 10, 4287; b) C. Zhang, K. Zhao, W. Bu, D. Ni, Y. Liu, J. Feng, J. Shi, Angew. Chem. Int. Ed. 2015, 54, 1770. [5] a) X.-D. Zhang, Z. Luo, J. Chen, X. Shen, S. Song, Y. Sun, S. Fan, F. Fan, D. T. Leong, J. Xie, Adv. Mater. 2014, 26, 4565; b) X.-D. Zhang, J. Chen, Y. Min, G. B. Park, X. Shen, S.-S. Song, Y.-M. Sun, H. Wang, W. Long, J. Xie, K. Gao, L. Zhang, S. Fan, F. Fan, U. Jeong, Adv. Funct. Mater. 2014, 24, 1718; c) M. F. Chung, H. Y. Liu, K. J. Lin, W. T. Chia, H. W. Sung, Angew. Chem. Int. Ed. 2015, 54, 10028; d) E. C. Wang, Y. Min, R. C. Palm, J. J. Fiordalisi, K. T. Wagner, N. Hyder, A. D. Cox, J. M. Caster, X. Tian, A. Z. Wang, Biomaterials 2015, 51, 208; e) Y. Dou, Y. Guo, X. Li, X. Li, S. Wang, L. Wang, G. Lv, X. Zhang, H. Wang, X. Gong, J. Chang, ACS Nano 2016, 10, 2536; f) G. Song, Q. Wang, Y. Wang, G. Lv, C. Li, R. Zou, Z. Chen, Z. Qin, K. Huo, R. Hu, J. Hu, Adv. Funct. Mater. 2013, 23, 4281; g) G. Song, J. Hao, C. Liang, T. Liu, M. Gao, L. Cheng, J. Hu, Z. Liu, Angew. Chem. Int. Ed. 2016, 55, 2122. [6] a) C. R. Gordijo, A. Z. Abbasi, M. A. Amini, H. Y. Lip, A. Maeda, P. Cai, P. J. O’Brien, R. S. DaCosta, A. M. Rauth, X. Y. Wu, Adv. Funct. Mater. 2015, 25, 1858; b) W. Fan, W. Bu, B. Shen, Q. He, Z. Cui, Y. Liu, X. Zheng, K. Zhao, J. Shi, Adv. Mater. 2015, 27, 4155; c) G. Song, C. Liang, H. Gong, M. Li, X. Zheng, L. Cheng, K. Yang, X. Jiang, Z. Liu, Adv. Mater. 2015, 27, 6110; d) G. Song, C. Liang, X. Yi, Q. Zhao, L. Cheng, K. Yang, Z. Liu, Adv. Mater. 2016, 28, 2716; e) M. Song, T. Liu, C. Shi, X. Zhang, X. Chen, ACS Nano 2016, 10, 633; f) C. C. Huang, W. T. Chia, M. F. Chung, K. J. Lin, C. W. Hsiao, C. Jin, W. H. Lim, C. C. Chen, H. W. Sung, J. Am. Chem. Soc. 2016, 138, 5222. [7] a) N. Lee, H. R. Cho, M. H. Oh, S. H. Lee, K. Kim, B. H. Kim, K. Shin, T. Y. Ahn, J. W. Choi, Y. W. Kim, S. H. Choi, T. Hyeon, J. Am. Chem. Soc. 2012, 134, 10309; b) M. H. Oh, N. Lee, H. Kim, S. P. Park, Y. Piao, J. Lee, S. W. Jun, W. K. Moon, S. H. Choi, T. Hyeon, J. Am. Chem. Soc. 2011, 133, 5508; c) J. D. Freedman, H. Lusic, B. D. Snyder, M. W. Grinstaff, Angew. Chem. Int. Ed. 2014, 53, 8406; d) P. J. Bonitatibus Jr., A. S. Torres, B. Kandapallil, B. D. Lee, G. D. Goddard, R. E. Colborn, M. E. Marino, ACS Nano 2012, 6, 6650. [8] a) I. Jiménez-Morales, M. Moreno-Recio, J. Santamaría-González, P. Maireles-Torres, A. Jiménez-López, Appl. Catal. B-Environ. 2014, 154, 190; b) J. Kang, Y. Rao, M. Trudeau, D. Antonelli, Angew. Chem. Int. Ed. 2008, 47, 4896.\n[9] R. E. Brown, K. L. Jarvis, K. J. Hyland, Anal. Biochem. 1989, 180, 136. [10] a) X. Yang, Z. Cai, Z. Ye, S. Chen, Y. Yang, H. Wang, Y. Liu, A. Cao,\nNanoscale 2012, 4, 414; b) F. P. Chang, Y. P. Chen, C. Y. Mou, Small 2014, 10, 4785. [11] L. Goth, Clin. Chim. Acta 1991, 196, 143. [12] C. Southan, Drug Discov. Today 2001, 6, 681. [13] M. Lopez-Lazaro, Cancer Lett. 2007, 252, 1. [14] a) X. D. Wang, K. S. Rabe, I. Ahmed, C. M. Niemeyer, Adv. Mater.\n2015, 27, 7945; b) Y. Anraku, A. Kishimura, M. Kamiya, S. Tanaka, T. Nomoto, K. Toh, Y. Matsumoto, S. Fukushima, D. Sueyoshi, M. R. Kano, Y. Urano, N. Nishiyama, K. Kataoka, Angew. Chem. Int. Ed. 2016, 55, 560. [15] a) J. Liu, S. Z. Qiao, J. S. Chen, X. W. D. Lou, X. Xing, G. Q. M. Lu, Chem. Commun. 2011, 12578; b) X. W. Lou, L. A. Archer, Z. C. Yang, Adv. Mater. 2008, 20, 3987."
    } ],
    "references" : [ ],
    "referenceMentions" : [ ],
    "year" : 2016,
    "abstractText" : "Dr. G. Song, Y. Chen, C. Liang, J. Liu, X. Sun, S. Shen, Prof. Z. Liu Institute of Functional Nano and Soft Materials (FUNSOM) Collaborative Innovation Center of Suzhou Nano Science and Technology Soochow University Suzhou, Jiangsu 215123, P. R. China E-mail: zliu@suda.edu.cn X. Yi, Prof. K. Yang School of Radiation Medicine and Protection and School for Radiological and Interdisciplinary Sciences (RAD-X) Medical College of Soochow University Suzhou, Jiangsu 215123, P. R. China",
    "creator" : null
  }
}